A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors

Inclusion Criteria: * Have at least 1 injectable measurable cutaneous, subcutaneous or nodal lesion (direct injection or through the use of ultrasound guidance) not exceeding 50mm in longest diameter and whenever possible 1 distant non-injected measurable lesion. * Provision of a fresh tumor sample of the lesion that will be injected first and, whenever possible, from another lesion that is planned to be injected, at baseline and be willing to supply new tumor samples from a biopsy during treatment. * Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1. * Have adequate hematological, hepatic and renal functions. * Have histologically confirmed, advanced/metastatic sarcoma (soft tissue and bone), Merkel cell carcinoma, melanoma, triple negative breast cancer or non-small cell lung cancer, with cutaneous or, palpable subcutaneous lesions or easily injectable lymph nodes. * Have failed and/or are intolerant to standard therapeutic options. Exclusion Criteria: * Have had major surgery within 4 weeks of first study drug administration. * Have received prior treatment with a vaccinia oncolytic virus. * Have received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to the start of treatment. * Have received prior radiotherapy within 2 weeks of start of study treatment or have had a history of radiation pneumonitis * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceed…